Company news
Zhejiang Conba Pharmaceutical Co., Ltd. Class A (SSE:600572) news
Zhejiang Conba Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Resolutions of the 21st (Extraordinary) Meeting of the 11th Board of Directors
September 29, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 15, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Completion of Filing of Industrial and Commercial Registration Changes for the Transfer of 100% Equity Interest in Dongyang CONBA through Public Listing
August 31, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Key Operating Data for the First Half of 2026
August 25, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Progress in Public Listing for Transfer of 100% Equity in Dongyang Kang'enbei Printing and Packaging Co., Ltd.
August 17, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Indicative Announcement on the Restricted Exercise Period under the 2022 Stock Option Incentive Plan
August 4, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Clinical Trial for New Indication of Shexiang Tongxin Dropping Pills by Subsidiary
July 24, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Subsidiary's Rivaroxaban Tablets Obtaining Supplementary Approval for Additional Specifications and Other Matters
July 13, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Inclusion of Products of the Company and Its Subsidiaries in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Execution of the License, Development and Commercialization Agreement for Cebranopadol in Greater China by Subsidiaries Hangzhou CONBA and Hong Kong CONBA with Adneuris
July 6, 2026
"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
July 3, 2026
"Zhejiang CONBA Pharmaceutical Co.,Ltd."Announcement on Self-exercise Results of Stock Option Incentive Plan and Share Changes for Q2 2026
July 1, 2026
Announcement on Resolutions of the 18th (Extraordinary) Meeting of the 11th Board of Directors
June 17, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 16, 2026
Announcement on the Public Listing and Transfer of 100% Equity Interest in Dongyang Conba
June 8, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 5, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 13, 2026
Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
May 8, 2026
Report for Q1 2026
April 22, 2026
Announcement on Subsidiary Obtaining Drug Registration Certificate for Telmisartan Amlodipine Tablets (III)
April 9, 2026
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q1 2026 and Share Changes
April 1, 2026
Indicative Announcement on Restricted Exercise Period of Stock Option Incentive Plan of 2022
March 31, 2026
Announcement on Results of Shareholding Reduction by Shareholders
March 10, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
March 6, 2026
Announcement on a Subsidiary Obtaining the Drug Registration Certificate for Esomeprazole Magnesium Enteric Capsules
February 26, 2026
Announcement on Drugs of the Subsidiary Being Selected for National Procurement Continuation After the Expiry of Agreement
February 12, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 9, 2026
Announcement on Subsidiary’s TFA003 Tablets Obtaining the Notice of Approval for Drug Clinical Trials
February 4, 2026
Announcement on Release of Pledge of Partial Equity Held by Shareholders
January 29, 2026
Announcement on Resolutions of the 15th (Extraordinary) Meeting of the 11th Board of Directors
January 23, 2026
Announcement on the Results of Controlling Shareholder Zhejiang Medical & Health Group's Share Increase and Equity Change Reaching 1% Scale
January 16, 2026
Announcement on Amending the "Articles of Association", Changing the Legal Representative, Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
January 13, 2026
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q4 2025 and Share Changes
January 5, 2026
Announcement on Election of Chairman, Vice Chairman, and Other Matters
December 30, 2025
Announcement on Propiverine Hydrochloride Inhalation Solution Obtaining Drug Registration Certificate by Subsidiary
December 29, 2025
Announcement on Proposed Shareholding Increase Plan by the Controlling Shareholder Zhejiang Medicine Group through Block Trading
December 22, 2025
Announcement on Resignation Matters of Chairman, Legal Representative and Other Personnel
December 5, 2025
Announcement on Notifying Creditors of Registered Capital Reduction
November 28, 2025
Announcement on Implementation of Independent Exercise in the 2nd Exercise Period of Stock Options Initially Granted in 2022 Stock Option Incentive Plan
November 24, 2025
Announcement on the Completion of Cancellation of Some Stock Options under the 2022 Stock Option Incentive Plan
November 13, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 11, 2025
Announcement on Compliance with Exercise Conditions for the 1st Vesting Period of Stock Options Reserve Granted under 2022 Stock Option Incentive Plan
November 6, 2025
Announcement on Resolutions of the 11th (Extraordinary) Meeting of the 11th Board of Directors
October 28, 2025
Indicative Announcement on Restricted Exercise Period for the First Vesting Period of Stock Options Initially Granted in 2022 Stock Option Incentive Plan
October 17, 2025
Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q3 2025 and Share Changes
October 9, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing and Collection of Questions
September 15, 2025
Announcement on Approval for Registration of Ultra-short-term Financing Bonds and Medium-term Notes
September 10, 2025
Announcement on Subsidiary's Obtainment of Drug Registration Certificate for Compound Ipratropium Bromide Solution for Inhalation
September 8, 2025
Announcement on Obtaining Drug Registration Certificate for Linggui Zhugan Decoction Granules
September 3, 2025
Full Text of the Semi-annual Report
August 27, 2025